SGLT2 Inhibitors in Cardiovascular Disease – Who, What, When, Where, and Why?


This presentation will review the literature describing the use of sodium-glucose co-transporter-2 inhibitors in patients with cardiovascular diseases. The presentation will help learners to identify which patients are most likely to benefit from treatment, anticipate patient-specific barriers, and promote optimal patient outcomes.

Learning Objectives

  • Identify patients most likely to benefit from SGLT2 Inhibitors
  • Describe the benefits of SGLT2 Inhibitors beyond glucose lowering in patients with diabetes, chronic kidney disease, or heart failure
  • Anticipate common risks for a patient taking SGLT2 Inhibitors
  • Develop a plan for monitoring outcomes in patients taking SGLT2 Inhibitors


Ben Van Tassell, PharmD
Professor and Vice-Chair of Research
Virginia Commonwealth University

Registration Rates

VPhA Member: $20
Non-Member: $35

Click here to register if cannot see the LecturePanda button below.